GCP
INBX

GSA Capital Partners’s Inhibrx, Inc. Common Stock INBX Stock Holding History

GSA Capital Partners’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-19,068
Closed -$470K – 2085
2022
Q4 		$470K Buy
+19,068
New +$560K 0.06% 644

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

GSA Capital Partners's INBX Position: Q1 2023 in Review

GSA Capital Partners sold out of Inhibrx, Inc. Common Stock (INBX) in Q1 2023, closing a stake of 19,068 shares — an estimated $470K sold.

GSA Capital Partners first reported a position in INBX in Q4 2022 and held it in 1 quarter. The position peaked at $470K in Q4 2022. 108 funds tracked by Wall St. Rank hold INBX as of Q1 2023.

  • GSA Capital Partners reported no remaining Inhibrx, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • GSA Capital Partners sold 19,068 Inhibrx, Inc. Common Stock shares in Q1 2023, an estimated $470K.
  • GSA Capital Partners first reported a position in Inhibrx, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • GSA Capital Partners's Inhibrx, Inc. Common Stock position peaked at $470K in Q4 2022.
  • 108 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q1 2023.

Based on GSA Capital Partners's 13F filing for Q1 2023, filed 12 May 2023.